Curative Effect of Entecavir plus Thymosin α1 for Patients with Chronic Hepatitis B

Objective:To observe the effect of entecavir and thymosin α1 treatment HBeAg positive chronic patitis B patients.Methods:58 HBeAg-positive patients with chronic hepatitis B were divided into combination group(n=28) and control group(n=30).The combination group was treated with entecavir and thymosin α1 for 24 weeks,and then stopping using thymosin α1 and continuing entecavir until 48 weeks;the control group was given entecavir(0.5mg daily) for 48 weeks,regularly testing the recovery rate ofALT,HBV DNA negative conversion rate,HBeAg/anti-HBe seroconversion rate,combination of hepatic fibrosis.Results:At 24 weeks there were no difference in the recovery rate of ALT between the two groups(P 0.05),There were respectively significant differences between the two group patients both HBeAg seroconversion rates and HBV DNA negative rate at 24 weeks,48 weeks(P0.05).The levels of liver fibrosis indexes(HA,LN,PⅢP,Ⅳ-collagen)and fibroscan score decreased significantly after treatment for 48 weeks of two treatment groups,The differences were statistically significant(P 0.05).No adverse reaction was reported during the treatment.Conclusions:Entecavir and thymosin α1 for HBeAg positive chronic hepatitis B have a good safety and tolerability,the combination group in the rate of ALT normalization,HBeAg seroconversion and HBV DNA negative rate,the efficacy of hepatic fibrosis is significantly superior to the entecavir group alone.